These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3094042)

  • 1. Plasma and tissue levels of flecainide in rats.
    Piovan D; Padrini R; Furlanut M; Moretto R; Ferrari M
    Pharmacol Res Commun; 1986 Aug; 18(8):739-45. PubMed ID: 3094042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism of flecainide.
    Conard GJ; Ober RE
    Am J Cardiol; 1984 Feb; 53(5):41B-51B. PubMed ID: 6364769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of flecainide in patients with mild and moderate renal failure compared with patients with normal renal function.
    Braun J; Kollert JR; Becker JU
    Eur J Clin Pharmacol; 1987; 31(6):711-4. PubMed ID: 3104059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man.
    Tjandra-Maga TB; Verbesselt R; Van Hecken A; Mullie A; De Schepper PJ
    Br J Clin Pharmacol; 1986 Sep; 22(3):309-16. PubMed ID: 3094570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of flecainide in patients with cirrhosis of the liver.
    McQuinn RL; Pentikäinen PJ; Chang SF; Conard GJ
    Clin Pharmacol Ther; 1988 Nov; 44(5):566-72. PubMed ID: 3141098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats.
    Egorin MJ; Lagattuta TF; Hamburger DR; Covey JM; White KD; Musser SM; Eiseman JL
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):7-19. PubMed ID: 11855755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic variability of flecainide assessed by QRS changes.
    Padrini R; Piovan D; Busa M; al-Bunni M; Maiolino P; Ferrari M
    Clin Pharmacol Ther; 1993 Jan; 53(1):59-64. PubMed ID: 8422742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enantioselective tissue distribution of the basic drugs disopyramide, flecainide and verapamil in rats: role of plasma protein and tissue phosphatidylserine binding.
    Hanada K; Akimoto S; Mitsui K; Mihara K; Ogata H
    Pharm Res; 1998 Aug; 15(8):1250-6. PubMed ID: 9706057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of intravenous flecainide in critically ill patients.
    Sangrador G; Sánchez-Alcaraz A; Rodriguez M; Ibáñez P
    J Clin Pharm Ther; 1989 Aug; 14(4):309-14. PubMed ID: 2507556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered flecainide disposition in healthy volunteers taking quinine.
    Munafo A; Reymond-Michel G; Biollaz J
    Eur J Clin Pharmacol; 1990; 38(3):269-73. PubMed ID: 2111245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dependent tissue uptake of flecainide during chronic administration in rabbits.
    Kannan R; Matin-Asgari A
    Drug Metab Dispos; 1988; 16(2):228-31. PubMed ID: 2898338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flecainide excretion in human breast milk.
    McQuinn RL; Pisani A; Wafa S; Chang SF; Miller AM; Frappell JM; Chamberlain GV; Camm AJ
    Clin Pharmacol Ther; 1990 Sep; 48(3):262-7. PubMed ID: 2119270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral flecainide pharmacokinetics in patients with impaired renal function.
    Forland SC; Burgess E; Blair AD; Cutler RE; Kvam DC; Weeks CE; Fox JM; Conard GJ
    J Clin Pharmacol; 1988 Mar; 28(3):259-67. PubMed ID: 3129455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered pharmacokinetics of oral flecainide by cimetidine.
    Tjandra-Maga TB; van Hecken A; van Melle P; Verbesselt R; de Schepper PJ
    Br J Clin Pharmacol; 1986 Jul; 22(1):108-10. PubMed ID: 3741720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma concentrations of flecainide acetate, a new antiarrhythmic agent, in humans.
    Conard GJ; Carlson GL; Frost JW; Ober RE; Leon AS; Hunninghake DB
    Clin Ther; 1984; 6(5):643-52. PubMed ID: 6478470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of oral dosage and pharmacokinetic analysis of flecainide in horses.
    Ohmura H; Hiraga A; Aida H; Takahashi T; Nukada T
    J Vet Med Sci; 2001 May; 63(5):511-4. PubMed ID: 11411495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-performance liquid chromatographic assay with fluorometric detection for flecainide and its major metabolites in urine and serum.
    Munafo A; Biollaz J
    J Chromatogr; 1989 May; 490(2):450-7. PubMed ID: 2504761
    [No Abstract]   [Full Text] [Related]  

  • 18. Absorption and enterohepatic circulation of baicalin in rats.
    Xing J; Chen X; Zhong D
    Life Sci; 2005 Nov; 78(2):140-6. PubMed ID: 16107266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved solid-phase extraction technique for plasma flecainide analysis by high-performance liquid chromatography.
    Wilson KM; Schneider JJ; Ravenscroft PJ
    Ther Drug Monit; 1998 Aug; 20(4):435-8. PubMed ID: 9712470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flecainide: evidence of non-linear kinetics.
    Boriani G; Strocchi E; Capucci A; Callivà R; Frabetti L; Ambrosioni E; Magnani B
    Eur J Clin Pharmacol; 1991; 41(1):57-9. PubMed ID: 1782978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.